The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| NCNA | -98.47% | -99.98% | -82.31% | -100% |
| S&P | +13% | +86.41% | +13.26% | +170% |
NuCana Plc is a clinical stage biopharmaceutical company. It engages in the business of developing a portfolio of new medicines to treat patients with cancer. The company was founded by Hugh Stephen Griffith and Christopher Barry Wood on January 28, 1997 and is headquartered in Edinburgh, the United Kingdom.
No news articles found for NuCana Plc.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.09M | 47.0% |
| Market Cap | $8.85M | -1.9% |
| Market Cap / Employee | $0.40M | 0.0% |
| Employees | 22 | -21.4% |
| Net Income | -$0.38M | 93.5% |
| EBITDA | -$4.72M | 26.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $33.99M | 123.3% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.08M | -55.7% |
| Short Term Debt | $0.10M | -10.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -104.84% | -7.7% |
| Return On Invested Capital | -134.76% | -57.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $1.59M | 127.5% |
| Operating Free Cash Flow | $1.59M | 127.5% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.90 | 0.98 | 5.58 | 2.25 | 45.63% |
| Price to Tangible Book Value | 328.83 | 210.15 | 27.17 | 1.25 | -99.76% |
| Enterprise Value to EBITDA | 1.00 | -0.12 | -0.03 | 3.53 | 142.66% |
| Return on Equity | -183.1% | -205.0% | -563.3% | -179.4% | -11.52% |
| Total Debt | $0.24M | $0.22M | $0.21M | $0.18M | -38.24% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
